Fusion Pharmaceuticals Inc. Research and Development in Process
Fusion Pharmaceuticals Inc. reported Research and Development in Process of $1.28 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-16.
Discontinued › Notes
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-03-16
- Fusion Pharmaceuticals Inc. research and development in process for the quarter ending 2022-12-31 was $0.00.
- Fusion Pharmaceuticals Inc. research and development in process for the quarter ending 2021-12-31 was $0.00.
- Fusion Pharmaceuticals Inc. research and development in process for the quarter ending 2021-09-30 was $0.00.
- Fusion Pharmaceuticals Inc. research and development in process for fiscal 2022 was $1.28M, a 85.60% decline from fiscal 2021.
- Fusion Pharmaceuticals Inc. research and development in process for fiscal 2021 was $8.92M.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $1.28M 10-K · filed 2023-03-16 | ||
| 2022-09-30 | $1.28M 10-Q · filed 2022-11-08 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-16 | $8.92M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $8.92M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $8.92M 10-Q · filed 2022-08-09 |